On March 11, 2020, the World Health Organization declared the COVID-19 outbreak as a pandemic. Coronavirus disease 2019 (COVID-19) has negative effect on patients with ST-segment elevation myocardial<unk>  (STEMI). STEMI can be the first manifestation of COVID-19. Reported case series addressed the significant reduction of  STEMI presentation and cath lab activation rate during  first wave of pandemic period. So, the number of out-of hospital cardiac arrest increased due to late presentation of STEMI in italy. Additionally, there was an increased incidence of acute thrombotic STEMI among patients undergoing coronary angiography suggestive of increased inflammation and platelet activation and direct viral interaction with ACE2 receptors. However, one-third of STEMI patients undergoing angiography had non-obstructive culprit lesion indicating of type2 myocardial<unk> , myocarditis secondary to SARS-COV-2 infection, SARS-COV-2 related endothelial dysfunction, or cytokine storm. STEMI patients with confirmed COVID-19  presented with lower conventional risk factors and were more likely to present with  deteriotated clinical status and higher killip class and progression to cardiogenic shock as well as higher mortality rate due to  COVID-19 thrombogenicity and high thrombisis burden in coronary arteries.
COVID-19-associated myocardial infarction
COVID-19-associated myocardial injury
COVID-19-associated myocarditis
COVID-19-associated hemodialysis
COVID-19-associated cardiogenic shock
COVID-19-associated heart failure
COVID-19-associated cytokine storm
COVID-19-associated stroke